Rates of first infection following kidney transplant in the United States  by Snyder, Jon J. et al.
Rates of first infection following kidney transplant in
the United States
Jon J. Snyder1, Ajay K. Israni2,3, Yi Peng1, Lin Zhang4, Teresa A. Simon4 and Bertram L. Kasiske2
1Chronic Disease Research Group, Minneapolis Medical Research Foundation, Minneapolis, Minnesota, USA; 2Department of Medicine,
Hennepin County Medical Center, University of Minnesota, Minneapolis, Minnesota, USA; 3Division of Epidemiology and Community
Health, School of Public Health, University of Minnesota, Minneapolis, Minnesota, USA and 4Pharmacovigilance, Bristol-Myers Squibb
Company, Princeton, New Jersey, USA
We studied the incidence, trends and clinical correlates of
infections following kidney transplantation in the United
States Renal Data System over the years 1995–2003 in 46,471
adults with Medicare primary coverage at the time of their
first kidney transplant. The incidence of most infections has
declined only slightly since 1995 but infection with
cytomegalovirus significantly declined while that with
hepatitis C significantly increased. Relative frequencies of
different types of infections (bacterial, viral, fungal and
parasitic) were relatively constant, both during early and late
periods following transplant. Using the Cox proportional
hazards analysis we found that the clinical correlates for post-
transplant bacterial and viral infections included older age,
female gender, diabetes as the cause of end-stage renal
disease, deceased (vs. living) donor source, time on dialysis
before transplant, hepatitis B and C viral pre-transplant
serologic status and pre-transplant donor-recipient
cytomegalovirus serology. Our study shows that despite
identifiable risk factors, the incidence of most post-transplant
infections has changed little since 1995.
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Over the past 20 years, 1-year graft survival for deceased-donor
kidney transplant recipients improved by 41%,1 and by 10% for
living-donor recipients,2 no doubt due to the dramatic decline
in incidence of acute rejection.3 However, survival with a
functioning graft beyond the first year has changed little,4 and
attention has shifted toward management of immunosuppres-
sion and complications that may affect long-term graft survival
and patient morbidity. As a cause of graft failure, death with
function is almost as frequent as return to dialysis or
retransplant, and post-transplant infection is second only to
cardiovascular disease as the most common cause of death after
kidney transplant.5 Although various studies have assessed
specific post-transplant infections,6–14 few studies have assessed
overall incidence and trends in infections after kidney
transplant.15–21 Therefore, in this study, we examined trends
and risk factors for post-transplant infections in adult kidney
transplant patients in the United States.
RESULTS
The cohort included 46,471 adult (aged X18 years) first
kidney transplant patients, 1995–2003 with Medicare Part A
(hospital insurance) and Part B (medical insurance) primary
coverage at the time of transplant.
Infection rates during post-transplant years 1–3
Infections identified by causative agent (for example,
bacterial, viral, fungal, or parasitic) occurred at a rate of
45.0 per 100 patient-years of follow-up (Table 1), as
estimated during years 1–3 post-transplant. The linear trend
in the overall infection rate during the study period was
declining (P¼ 0.0007), but the yearly infection rate peaked in
1997 and remained fairly constant during 1998–2001.
Bacterial infections were the most common type during 3-
year follow-up for 1995–2001, with approximately 23.2 first
bacterial infections per 100 patient-years for the entire
cohort. The bacterial infection rate showed a slight down-
ward trend over the study period (P¼ 0.0006). Septicemia
(organisms listed in Appendix A) was the most common
bacterial infection, 11.2 per 100 patient-years, accounting for
nearly half of all bacterial infections. The septicemia rate also
showed a downward trend (P¼ 0.0055).
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Viral infections were the second most common type, 18.1
infections per 100 patient-years for 1995–2001. Cytomegalo-
virus (CMV) infection was the most common viral infection,
6.6 per 100 patient-years. The CMV infection rate declined
from 8.3 per 100 patient-years in 1995 to 5.9 per 100 patient-
years in 2001. In contrast, hepatitis B virus (HBV) infection
rates increased from 0.4 per 100 patient-years in 1995 to 1.0
per 100 patient-years in 2001, and hepatitis C virus (HCV)
infection rates more than doubled from 1.3 per 100 patient-
years in 1995 to 3.3 per 100 patient-years in 2001. Herpes
simplex infection rates declined, and varicella-zoster infec-
tion rates declined after an initial increase during 1995–1997.
Fungal infection rates changed little over the time period,
5.3 fungal infections per 100 patient-years of follow-up.
Candidiasis accounted for 77% of fungal diagnoses; candi-
diasis of the mouth (thrush) accounted for 43% of fungal
diagnoses. Fungal infections were noted as disseminated
candidiasis in 3% of cases and histoplasmosis in 2%. Parasitic
infections were the least common type (o1 patient per 100
patient-years of follow-up), and rates showed a downward
trend. Pneumocystosis infections were rare, with only 0.3
cases per 100 patient-years of follow-up.
Two secondary analyses were performed to examine
sensitivities to the methodology (data not shown). First, we
examined infection rates as identified on inpatient claims
only (not necessarily primary discharge diagnoses). Trends
generally paralleled those shown in Table 1, and the overall
infection rate as identified by hospitalization claims was 44%
lower than the overall rate shown in Table 1. By infection
type, the rates of hospitalizations with bacterial, viral, fungal,
and parasitic infections were 35, 51, 44, and 70% lower than
the rates estimated from both inpatient and outpatient
claims, respectively.
Second, we examined infection rates as identified on any
inpatient or outpatient claim. In the primary analysis, in the
absence of an inpatient claim, two outpatient claims on
separate days were required, to avoid counting suspected but
not confirmed infections. This less restrictive criterion,
allowing one outpatient claim in the absence of an inpatient
claim, increased the overall infection rate for the entire
period, 1995–2001, by 10%, from 45 infections per 100
patient-years to 49 per 100 patient-years. Rates of viral,
bacterial, fungal, and parasitic infections increased by 25, 19,
9, and 37%, respectively, absolute differences of 4.5, 4.3, 0.5,
and 0.3 infections per 100 patient-years, respectively.
Infection rates by post-transplant year
Rates were highest in post-transplant year 1 for all major
infection types, and remained relatively constant in sub-
sequent post-transplant years (Table 2). Trends in first-year
infection rates during 1995–2002 (Figure 1) indicate declines
in bacterial, viral, and parasitic infections (Po0.0001), but
little change in fungal infection rates (P¼ 0.0922). Figure 1
data differ from Table 1 data in that Figure 1 represents rates
estimated during post-transplant year 1 only, and Table 1
years 1–3.
Infection-caused hospitalization in post-transplant years 1–3
All hospitalizations with infection as a primary discharge
diagnosis were analyzed separately. For this analysis,
nonspecific diagnoses such as urinary tract infection (UTI),
pneumonia, or postoperative infection, with causative agents
not necessarily defined, were included. Of these hospitaliza-
tions, UTI was the most common reason for infection-caused
hospitalizations during post-transplant year 1, followed
closely by pneumonia, postoperative infection, and septice-
Table 1 | Trends in rates of infection (per 100 patient-years) during post-transplant years 1–3
Transplant year
Infection 1995–2001 1995 1996 1997 1998 1999 2000 2001 Pa
Any 45.0 46.3 47.7 48.4 43.1 44.0 43.0 45.3 0.0007
Bacterial 23.2 24.6 24.4 24.4 22.3 23.0 22.4 23.1 0.0006
Septicemia 11.2 11.9 12.0 11.9 10.5 11.4 10.9 11.0 0.0055
Tuberculosis 0.8 0.9 1.1 0.9 0.8 0.6 0.6 0.6 o0.0001
Other bacterial 15.4 15.4 15.6 15.9 15.3 15.6 15.2 15.7 0.8700
Viral 18.1 18.2 19.4 19.4 17.7 17.0 17.0 18.5 0.0166
Varicella-zoster 3.4 2.9 3.5 3.5 3.4 3.4 3.3 3.3 0.6329
Herpes simplex 2.4 2.7 2.6 2.7 2.3 2.2 2.1 2.3 0.0007
Hepatitis, not B or C 0.3 0.2 0.3 0.2 0.3 0.2 0.2 0.3 0.7469
Hepatitis B 0.7 0.4 0.5 0.8 0.7 0.8 0.7 1.0 o0.0001
Hepatitis C 2.4 1.3 1.8 2.2 2.5 2.4 3.1 3.3 o0.0001
HIV 0.6 0.7 0.6 0.6 0.6 0.6 0.6 0.8 0.2100
Cytomegalovirus 6.6 8.3 8.1 7.8 6.1 5.9 5.4 5.9 o0.0001
Other viral 2.5 2.5 2.7 2.7 2.5 2.4 2.5 2.4 0.1619
Fungal 5.3 5.6 5.2 5.5 4.8 5.3 5.4 5.4 0.7589
Parasitic 0.8 1.0 0.9 1.0 0.6 0.7 0.9 0.7 0.0035
Pneumocystosisb 0.3 0.3 0.4 0.3 0.2 0.2 0.4 0.2 0.1878
Other parasitic 0.5 0.7 0.5 0.7 0.5 0.5 0.5 0.5 0.0065
HIV, human immunodeficiency virus.
aTest for linear trend over the time period. Infection rates were standardized to the characteristics of the 2002 transplant cohort by age, sex, race, primary cause of renal
failure, donor type, and prior dialysis time to facilitate comparisons across years.
bThe causative agent P. carinii was reclassified as a fungus in 2001 and renamed P. jiroveci.62
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mia (Figure 2). Pneumonia was the most common reason for
infection-caused hospitalizations during post-transplant
years 2 and 3, followed by UTI, septicemia, and cellulitis.
Hospitalizations with CMV as the primary cause were more
common in post-transplant year 1 than in subsequent years.
Clinical correlates of post-transplant infections
Factors associated with more than a 15% increase in the rate
of any type of infection during post-transplant year 1
included older age, sex, cause of end-stage renal disease
(ESRD), donor source (deceased vs living), pretransplant
time on dialysis, HBV and HCV serologic status, and
pretransplant donor–recipient CMV serology (Table 3). Older
age at the time of transplant was associated with higher
bacterial and fungal infection rates in year 1, but there was no
strong relationship between age and viral or parasitic
infections. Infection rates for patients with ESRD caused by
diabetes were generally higher than rates for patients with
kidney failure from other causes, largely attributable to
higher rates of bacterial (16–39% higher) and fungal (16–45%
higher) infections; viral infection rates were 7–17% lower.
Bacterial infection rates were 57% (38–78%) higher for
patients with dialysis duration 3 years or longer than for
patients undergoing preemptive transplants, and fungal
infection rates were 26% (0–59%) higher. Pretransplant
HBV and HCV serology was associated with increased rates
of all infection types except parasitic. Interestingly, pretrans-
plant CMV serologic status affected not only viral infection
rates (expected, as CMV is a virus), but also bacterial and
fungal infection rates (Table 3).
Differences associated with race or ethnicity were generally
small. Viral and fungal infection rates were lower for
Hispanic than for non-Hispanic patients; bacterial and
parasitic infection rates were comparable. Bacterial infection
rates for patients whose most recent panel reactive
antibodies value was X10% were slightly increased, with
no significant differences in rates of other infection types
(Table 3).
Assessment of immunosuppressive medications was
limited to medications prescribed at the time of transplant.
No differences were observed in infection rates with regard to
steroid use. Tacrolimus was associated with slightly lower
rates of viral, bacterial, and fungal infections than cyclospor-
ine; viral and bacterial infection rates were higher for patients
not given a calcineurin inhibitor. Compared with azathiopr-
ine users, mycophenolate mofetil users had 10% (3–16%)
higher rates of viral infections and 10% (1–19%) lower rates
Table 2 | Infection rates by year post-transplant, 1995–2003
Incidence rate (per 100 patient-years)
Infection type, age group (year) Year 1 Year 2 Year 3 Year 4 Year 5 Pa
Any
X18 74.7 33.1 29.6 NE NE o0.0001
X62 80.2 36.8 31.5 32.4 31.7 o0.0001
Bacterial
X18 37.5 18.3 17.4 NE NE o0.0001
X62 46.5 21.9 19.7 20.1 22.3 o0.0001
Viral
X18 32.4 13.9 11.3 NE NE o0.0001
X62 29.3 13.6 11.4 11.1 8.9 o0.0001
Fungal
X18 8.9 4.0 3.7 NE NE o0.0001
X62 10.6 5.4 4.4 3.4 3.9 o0.0001
Parasitic
X18 1.2 0.7 0.6 NE NE o0.0001
X62 1.2 0.4 0.3 0.4 0.5 o0.0001
NE, noneligible for Medicare as primary insurance coverage.
aTest for linear trend across post-transplant years. Infection rates were standardized to the characteristics of the 2002 transplant cohort by age, sex, race, primary cause of
renal failure, donor type, and prior dialysis time.
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Figure 1 | Trends in infection rates per 100 patient-years
during post-transplant year 1, 1995–2002.
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of fungal infections. Viral infection rates for patients using a
mammalian target of rapamycin inhibitor were 10% (3–17%)
lower than for patients not using a mammalian target of
rapamycin inhibitor, and bacterial infection rates were 27%
(18–36%) higher. Patients with no induction antibodies at the
time of transplant had slightly higher bacterial and fungal
infection rates. Use of IL-2 receptor antibodies (basiliximab
or daclizumab) was associated with slightly higher viral and
bacterial infection rates than use of other types of induction
antibodies, mainly thymoglobulin (anti-thymocyte globulin
(rabbit); Genzyme, Cambridge, MA, USA) after 1999, and
OKT3 (muromonab-CD3; eBioscience Inc., San Diego, CA,
USA) or Atgam (lymphocyte immune globulin, anti-
thymocyte globulin (equine); Pfizer, New York, NY, USA)
before 1999.22 As this study is observational and nonrando-
mized, associations between all immunosuppressive medica-
tions and infection rates should be interpreted cautiously.
DISCUSSION
Several findings in this study are important. (1) Since 1995,
overall incidence of bacterial and viral infections during post-
transplant year 1 has declined only modestly. Incidence of
bacterial sepsis declined slightly. Incidence of CMV and
herpes simplex virus infections declined, but incidence of
HBV and especially HCV infections increased. (2) Bacterial
and viral post-transplant infections are by far the most
common types; fungal and parasitic infections are less
common. Relative frequencies of infection types (bacterial
vs viral vs fungal vs parasitic) remain constant, each type
roughly twofold higher in post-transplant year 1 than in
subsequent years. Fishman and Rubin23 discussed how types
of infections vary during post-transplant year 1. Our study
finds that relative frequency of infection types remains fairly
constant across post-transplant years 1–5 when considering
yearly rates. (3) The most common reasons for infection-
caused hospitalizations are UTI in post-transplant year 1 and
pneumonia in years 2 and 3. Sepsis is the third leading cause
in years 1–3.
Among the most notable trends in the changing infection
incidence over time were the declines in herpes simplex and
CMV infection incidence during 1995–2003. This is un-
surprising, given the efficacy of antiviral prophylaxis
increasingly implemented during the study period.24 In
contrast, HBV and HCV infections increased during
1995–2003. The increase in HCV infections was not due to
more patients being HCV seropositive at the time of
transplant; this percentage remained constant (about 5.5%)
during 1995–2001 (test for trend, P¼ 0.64; data not shown).
Similarly, the percentage of HCV-antibody-positive donors
remained approximately 2% (minimum 1.7% in 1995, 2001,
and 2002; maximum 2.4% in 1998; test for trend, P¼ 0.08).
Given these constant percentages, hypothesizing reasons for
the observed increasing trend in the HCV rate is difficult.
Possibly, a global increase in immunosuppression (to reduce
acute rejection) during this time increased HCV likelihood,
thereby increasing incidence of clinically detectable disease
despite the number of seropositive patients remaining
constant.
Tacrolimus use increased compared with cyclosporine use
over our study timeframe;22 as cyclosporine, but not
tacrolimus, has been shown to have antiviral effects on
HCV replication in vitro,25 this change could be associated
with the increased HCV incidence. However, mycophenolate
mofetil use also increased over the study period, and it has
also been shown to inhibit HCV replication in vitro.25 We did
not assess HCV infection rates by immunosuppressive
regimen. This issue may warrant future exploration, as
neither cyclosporine nor mycophenolate mofetil has been
shown to have an antiviral effect in vivo. The increasing trend
may simply reflect changes in HCV monitoring and billing,
with artificially increased rates appearing in Medicare claims.
The percentage of patients who were HBV core antibody
positive (indicating past HBV infection) at the time of
transplant increased from 5% in 1995 to 8% in 2000 and 10%
in 2003 (test for trend, Po0.0001). The percentage of
patients who were HBsAg seropositive (indicating active
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Figure 2 | Infectious hospitalizations by cause and post-transplant year, calculated as a percent of all infectious hospitalization
events. CMV, cytomegalovirus; post-op, postoperative; resp, respiratory; UTI, urinary tract infection.
320 Kidney International (2009) 75, 317–326
o r i g i n a l a r t i c l e JJ Snyder et al.: Post-transplant infection
Table 3 | Associations with the incidence of infections during post-transplant year 1, 1995–2003 (n=46,471)a
Infection
Viral Bacterial Fungal Any
Characteristic (%)
Relative risk
(95% CI) P
Relative risk
(95% CI) P
Relative risk
(95% CI) P
Relative risk
(95% CI) P
Transplant era
1995–1998 (41.3) 1.00 1.00 1.00 1.00
1999–2003 (58.7) 0.91 (0.86–0.95) o0.0001 0.94 (0.89–0.98) 0.0051 1.07 (0.98–1.17) 0.1085 0.96 (0.93–0.99) 0.0185
Recipient age (years)
18–34 (18.4) 1.00 1.00 1.00 1.00
35–49 (31.7) 1.05 (0.99–1.12) 0.0750 1.01 (0.96–1.08) 0.6167 1.16 (1.04–1.30) 0.0079 1.07 (1.03–1.12) 0.0021
50–64 (35.6) 1.05 (0.99–1.11) 0.1285 1.24 (1.17–1.31) o0.0001 1.27 (1.13–1.42) o0.0001 1.15 (1.10–1.20) o0.0001
X65 (14.3) 1.05 (0.98–1.13) 0.1981 1.43 (1.34–1.53) o0.0001 1.42 (1.25–1.62) o0.0001 1.23 (1.16–1.29) o0.0001
Recipient sex
Women (39.9) 1.00 1.00 1.00 1.00
Men (60.1) 0.94 (0.90–0.98) 0.0016 0.79 (0.76–0.83) o0.0001 0.82 (0.77–0.89) o0.0001 0.84 (0.81–0.86) o0.0001
Recipient race
White (63.5) 1.00 1.00 1.00 1.00
African American (30.5) 1.02 (0.98–1.07) 0.3426 0.91 (0.87–0.96) o0.0001 1.06 (0.98–1.16) 0.1556 0.98 (0.94–1.01) 0.2052
Other/unknown (6.0) 1.03 (0.95–1.12) 0.5207 1.00 (0.92–1.08) 0.9606 0.85 (0.72–0.99) 0.0422 0.97 (0.91–1.03) 0.3294
Recipient ethnicity
Non-Hispanic (86.2) 1.00 1.00 1.00 1.00
Hispanic (13.8) 0.85 (0.80–0.90) o0.0001 1.00 (0.94–1.05) 0.8738 0.74 (0.65–0.83) o0.0001 0.90 (0.86–0.94) o0.0001
Cause of ESRD
Diabetes (26.1) 1.00 1.00 1.00 1.00
Hypertension (23.7) 1.07 (1.01–1.13) 0.0172 0.72 (0.68––0.76) o0.0001 0.79 (0.71–0.86) o0.0001 0.86 (0.83–0.90) o0.0001
Glomerulonephritis (25.2) 1.21 (1.14–1.28) o0.0001 0.66 (0.62–0.69) o0.0001 0.71 (0.64–0.78) o0.0001 0.87 (0.83–0.90) o0.0001
Cystic disease (7.4) 1.20 (1.10–1.30) o0.0001 0.65 (0.60–0.70) o0.0001 0.69 (0.59–0.80) o0.0001 0.81 (0.76–0.86) o0.0001
Other (17.7) 1.20 (1.13–1.27) o0.0001 0.86 (0.81–0.90) o0.0001 0.86 (0.77–0.95) 0.0039 0.99 (0.95–1.03) 0.6758
Donor type
Deceased (75.5) 1.00 1.00 1.00 1.00
Living (24.5) 0.86 (0.82–0.91) o0.0001 0.85 (0.81–0.89) o0.0001 0.81 (0.74–0.90) o0.0001 0.85 (0.81–0.88) o0.0001
Prior dialysis time (years)
0 (preemptive) (3.0) 1.00 1.00 1.00 1.00
o1 (11.6) 1.10 (0.96–1.26) 0.1512 1.16 (1.02–1.33) 0.0255 1.11 (0.87–1.42) 0.3901 1.15 (1.04–1.27) 0.0053
1–o2 (18.7) 1.13 (0.99–1.28) 0.0707 1.32 (1.16–1.50) o0.0001 1.17 (0.92–1.47) 0.1959 1.22 (1.10–1.34) o0.0001
2–o3 (19.6) 1.09 (0.96–1.25) 0.1795 1.42 (1.25–1.62) o0.0001 1.11 (0.88–1.40) 0.3929 1.26 (1.15–1.39) o0.0001
X3 (47.2) 1.05 (0.93–1.20) 0.4186 1.57 (1.38–1.78) o0.0001 1.26 (1.00–1.59) 0.0466 1.29 (1.18–1.42) o0.0001
Panel reactive antibody
o10% 1.00 1.00 1.00 1.00
X10% 1.00 (0.94–1.07) 0.9270 1.09 (1.03–1.16) 0.0032 1.08 (0.96–1.21) 0.1923 1.06 (1.01–1.11) 0.0170
Hepatitis serology
HBV core Ab+ (7.6) 1.25 (1.17–1.34) o0.0001 0.97 (0.91–1.05) 0.4631 0.91 (0.80–1.04) 0.1742 1.13 (1.08–1.19) o0.0001
HBV sAg+ (1.6) 1.39 (1.23–1.57) o0.0001 1.01 (0.87–1.16) 0.9167 1.21 (0.94–1.56) 0.1430 1.29 (1.17–1.42) o0.0001
HCV Ab+ (5.4) 36.6 (34.8–38.5) o0.0001 1.26 (1.16–1.37) o0.0001 1.40 (1.21–1.62) o0.0001 17.4 (16.6–18.2) o0.0001
Pretransplant CMV serology
Donor/Recipient (17.9) 1.00 1.00 1.00 1.00
Donor/Recipient+ (25.7) 1.11 (1.04–1.19) 0.0019 0.96 (0.90–1.01) 0.1386 1.03 (0.92–1.15) 0.6506 1.03 (0.98–1.08) 0.2037
Donor+/Recipient+ (37.4) 1.31 (1.23–1.39) o0.0001 1.06 (1.01–1.12) 0.0305 1.10 (0.99–1.22) 0.0788 1.15 (1.10–1.20) o0.0001
Donor+/Recipient– (19.0) 1.98 (1.85–2.11) o0.0001 1.18 (1.11–1.25) o0.0001 1.16 (1.03–1.30) 0.0134 1.45 (1.39–1.52) o0.0001
Steroid use
Steroids (92.4) 0.98 (0.90–1.07) 0.6721 0.95 (0.88–1.02) 0.1729 0.91 (0.78–1.06) 0.2287 0.95 (0.90–1.01) 0.1289
Calcineurin inhibitor use
Cyclosporine (52.5) 1.00 1.00 1.00 1.00
Tacrolimus (34.7) 0.93 (0.89–0.98) 0.0033 0.91 (0.87–0.95) o0.0001 0.85 (0.78–0.93) 0.0002 0.91 (0.88–0.94) o0.0001
Neither (12.8) 1.10 (1.03–1.18) 0.0030 1.09 (1.02–1.15) 0.0080 0.97 (0.86–1.09) 0.6354 1.06 (1.01–1.11) 0.0181
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infection) also increased slightly over the study period, from
1 to 2% (test for trend, Po0.0001). The increasing trends in
HCV and HBV infection rates are concerning, given the
deleterious effects HBV and HCV have on graft failure rates,
renal function, associated morbidity and patient out-
comes,20,26–48 and warrant further study.
Rates for all infection types were twice as high in post-
transplant year 1 than in years 2 and 3. For patients aged 62
years or older at the time of transplant, infection rates were
stable from post-transplant years 2–5, following the initial
decline after year 1. These findings are consistent with other
observations of elevated infection rates during post-trans-
plant year 1.13,15,20,21,49 Importantly, the relative frequency of
infection types was somewhat constant both before and after
transplant. That is, at any time after transplant, incidence was
highest for bacterial infections, which were slightly more
common than viral infections; bacterial and viral infections
were much more common than fungal infections, which were
slightly more common that parasitic infections (infection
incidence for bacterial 4viralbfungal4parasitic).
During post-transplant year 1, UTI was the leading cause
of infectious hospitalization, similar to earlier find-
ings.12,17,19,49,50 UTI has also been closely associated with
post-transplant septicemia.51 We found that the percent of
hospitalizations due to septicemia was only slightly lower
than the percent due to UTI. During post-transplant years 2
and 3, pneumonia was the leading cause of infectious
hospitalizations. Pneumonia occurring post-transplant year 1
has been shown to be associated with worse graft and patient
survival.13
Factors associated with an increase of more than 15% in
infection rates included older age, female sex, cause of ESRD,
donor source (deceased vs living), pretransplant time on
dialysis, HBV and HCV pretransplant serologic status, and
pretransplant donor–recipient CMV serology. Older patients
might be expected to be at increased risk for infection.
Women are likelier than men to have UTIs.49 Dharnidharka
et al.20 found women to be more often hospitalized for
bacterial infections than men, but hospitalization for viral
infections did not differ by sex. We found that women had
higher rates of all four infection types than men. The
association of ESRD caused by diabetes with increased
bacterial and fungal infection risk is also unsurprising, given
the high incidence of circulatory disorders, bladder dysfunc-
tion, and other problems among diabetic ESRD patients. Less
clear, however, is why ESRD caused by diabetes was
associated with a lower risk of viral infections. CMV
seropositivity prevalence was slightly higher for diabetic than
nondiabetic patients (65 vs 61%, Po0.0001); 56% of diabetic
and nondiabetic patients received kidneys from CMV-
seropositive donors (P¼ 0.56). Additional analyses are
warranted to explain lower viral infection rates among
diabetic patients.
Deceased-donor kidney recipients have more delayed graft
function and acute rejection, and likely receive more
immunosuppression. Our finding that they had higher
infection rates than living-donor kidney recipients is there-
fore unsurprising. Similarly, several studies have shown that
preemptive transplant is associated with better outcomes, and
our finding of fewer infections (especially viral) among
preemptive transplant patients should also be unsurprising.
Patients at risk for HBV or HCV at the time of transplant
could be expected to have higher incidence of viral infections
due to hepatitis.
Donor CMV seropositivity was associated with higher
rates of all types of infections, not just viral infections.
Although the risk was highest for CMV-antibody-positive
donors and CMV-antibody-negative recipients at the time of
Table 3 | Continued
Infection
Viral Bacterial Fungal Any
Characteristic (%)
Relative risk
(95% CI) P
Relative risk
(95% CI) P
Relative risk
(95% CI) P
Relative risk
(95% CI) P
Antimetabolite use
Azathioprine (15.2) 1.00 1.00 1.00 1.00
Mycophenolate mofetil (65.6) 1.10 (1.03–1.16) 0.0020 0.98 (0.93–1.04) 0.5383 0.90 (0.81–0.99) 0.0340 1.02 (0.98–1.07) 0.3608
Neither (19.2) 1.05 (0.98–1.13) 0.1510 1.07 (1.00–1.15) 0.0387 0.92 (0.80–1.04) 0.1852 1.06 (1.01–1.12) 0.0295
mTOR inhibitor use
Rapamycin (8.6) 0.90 (0.83–0.97) 0.0075 1.27 (1.18–1.36) o0.0001 1.04 (0.91–1.20) 0.5579 1.07 (1.02–1.14) 0.0099
Induction antibody
IL-2R blocker (23.8) 1.00 1.00 1.00 1.00
Other (24.4) 0.88 (0.83–0.93) o0.0001 0.95 (0.90–1.00) 0.0443 0.99 (0.90–1.09) 0.8566 0.93 (0.89–0.96) 0.0001
None (51.8) 1.04 (0.99–1.09) 0.1147 1.08 (1.03–1.13) 0.0007 1.10 (1.02–1.20) 0.0201 1.06 (1.03–1.10) 0.0005
CI, confidence interval; CMV, cytomegalovirus; HBV core Ab+, hepatitis B virus core antibody positive; HBV sAg+ , hepatitis B surface antigen positive; HCV Ab+, hepatitis C
virus antibody positive; IL-2R, interleukin-2 receptor; mTOR, mammalian target of rapamycin.
aResults of Cox proportional hazards analyses.
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transplant, the association remained when both donor and
recipient were CMV antibody positive. Dharnidharka et al.20
also described higher hospitalized viral and bacterial infec-
tion rates among recipients of CMV-antibody-positive
donors. Other authors have reported an association between
donor CMV seropositivity and fungal and bacterial outcomes
in liver transplantation.52–57 Nicols et al.58 found an
association between donor CMV seropositivity and fungal
infections in stem cell transplantation. Radisic et al.59 found
an association between CMV disease and pneumocystosis in
kidney transplant patients. Arend et al.60 also described a
relationship between Pneumocystis carinii pneumonia and
treatment of CMV disease. Our study confirms the relation-
ship between donor CMV seropositivity and fungal and
parasitic infections.
This study has some important limitations. Non-Medicare
patients were excluded due to the nature of the claims-based
outcome identification. We have shown previously that the
Medicare and non-Medicare transplant populations are
similar, but there are notable differences; Medicare bene-
ficiaries are slightly older, more likely to be members of racial
or ethnic minority groups, and more likely to receive
deceased-donor kidneys.61 Generalizing our findings to the
entire US kidney transplant population should therefore be
done cautiously; infection rates could be lower in the non-
Medicare population. As infections were identified through
Medicare claims, only those infections for which patients
sought treatment from healthcare providers, and which
healthcare providers noted on Medicare claims, could be
identified in this analysis. Thus, less severe infections and
infections not resulting in office visits were undercounted,
but the algorithm used to identify infections is likely highly
sensitive to more severe infections for which patients would
seek care. We were unable to assess the sensitivity and
specificity of the algorithm formally. Furthermore, although
facility claims (Part A) include up to 10 diagnosis codes and
carrier claims (Part B) include up to 4, we must assume that
infections were indeed coded on either facility or carrier
claims. Also of note, associations with baseline immunosup-
pression may be biased due to subsequent switches in therapy
that were not assessed in this analysis.
Additional limitations of using Medicare claims are that
we were unable to address use of prescription medications to
treat infections, and we were unable to address certain
infections of particular interest in solid organ transplanta-
tion, such as BK virus and Epstein–Barr virus, due to the lack
of specific International Classification of Disease, Ninth
Revision, Clinical Modification (ICD-9-CM) codes. Further,
presence of ICD-9-CM codes for the infections we were able
to assess does not convey any information regarding the
severity of the infection other than it was recognized by a
treating physician and noted on a Medicare claim. Despite
these limitations, Medicare claims-based analyses will con-
tinue to provide the best opportunity for monitoring post-
transplant infection rates in the United States, given
proposed changes in frequency and depth of patient follow-
up information collected by the Organ Procurement and
Transplantation Network.
In summary, viral, bacterial, and parasitic infection rates
in kidney transplant patients during post-transplant years 1–3
showed modest declines, whereas fungal infection rates
remained fairly constant. Incidence rates of CMV and herpes
simplex infections declined, whereas incidence rates of HCV
and HBV infections increased. Infection rates for all infection
types are twice as high in post-transplant year 1 as in
subsequent years. Importantly, the relative frequencies of
different infection types were similar at all times after
transplant. UTI is the most common reason for infectious
hospitalization in post-transplant year 1, and pneumonia in
years 2 and 3. Notable risk factors for post-transplant
infections include older age, female sex, diabetes as cause of
ESRD, donor source (deceased vs living), pretransplant time
on dialysis, HBV and HCV pretransplant serologic status, and
pretransplant donor–recipient CMV serology.
MATERIALS AND METHODS
Study population
The United States Renal Data System Standard Analytic Files were
used for this analysis. Medicare primary coverage was determined
through Medicare enrollment data and evidence of Medicare
primary status on transplant claims. The final cohort represented
40% of all adult kidney transplant patients in the United States
during the study time period.
Patients are eligible for Medicare coverage for up to 3 years after
transplant, unless they are otherwise Medicare eligible due to age or
disability status. Hence, infections were identified by searching
Medicare claims files during post-transplant years 1–3. Patients aged
62 years or older at the time of transplant (n¼ 9415) were studied
for 5 years after transplant, as they remained Medicare eligible.
Patients were followed until 31 December 2003, or the earliest of
transplant failure, death, or loss of Medicare coverage.
Identifying infections
Infections were identified by searching Medicare claims for ICD-9-
CM diagnosis codes for specific infections (Appendix A). The
primary assessment of infection rates by causative agent was limited
to the ICD-9-CM codes identifying infectious and parasitic diseases
(001.x–139.x) and did not include codes for more general
descriptors of infections such as pneumonia or UTI. If the organism
associated with a UTI (for example) was also identified by ICD-9-
CM code on the claim, that information was included. Patients were
positively identified as having a specific infection if one Part A
inpatient claim indicated an infection (excluding admitting
diagnosis); in the absence of a Part A inpatient claim, two
outpatient Part A or Part B claims within 1 year were required, to
minimize false-positive diagnoses based on one claim. The date of
the infection was the date of the inpatient claim or the second
outpatient claim.
Infectious hospitalizations
Infectious hospitalizations were identified by primary discharge
diagnoses indicating infection for all patients alive with functioning
grafts at the beginning of each of post-transplant year. Percentages of
specific infectious hospitalizations types were calculated as a
percentage of total hospitalizations and infectious hospitalizations
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due to UTI, pneumonia, postoperative infection, septicemia, CMV,
respiratory infection (other than pneumonia), cellulitis, vascular
access-related infection, kidney infection, and osteomyelitis.
This differs from the primary assessment of infection rates by
considering more general descriptors of infections, such as UTI and
pneumonia.
Infection rates
Only the first occurrence of each infection type was considered. The
time to any infection category (viral, fungal, bacterial, or parasitic)
was the time to the first occurrence in each category, as defined
above. All infections were considered incident cases, and patients
with evidence of infections before transplant were not excluded.
Infection rates were estimated by transplant year (calendar year) and
by post-transplant year in which the infection occurred. After
determining which patients showed evidence of specific infections,
the observed rate in group i is ni/yi, where ni is the event count in
group i and yi is the total observation time in group i. To allow for
more meaningful comparisons across time periods, adjusted rates
were estimated using a Poisson regression model with adjustment
for age, sex, race, primary cause of renal failure, donor type, and
prior dialysis time. Predicted rates were then standardized to the
characteristics of the 2002 transplant cohort by the same covariates
used in the Poisson regression model. Due to nonconstant hazards
over the 3-year follow-up period (infection rates were higher in
post-transplant year 1 than in years 2 and 3) rate estimates for the
entire 3-year follow-up period were not presented for the 2002 and
2003 cohorts because of reduced follow-up time, and first-year rates
were presented separately for all yearly cohorts.
To assess how infection rates vary with length of time after
transplant, rates were estimated for each year after transplant
through year 3 for all patients. For each year post-transplant, time to
first infection within the year was calculated and rates were
estimated from a Poisson regression model, as described above.
Patients with evidence of infection in any previous post-transplant
year were not excluded from each yearly estimate. Infection rates
were estimated for patients aged 62 years and older at the time of
transplant through 5 years after transplant.
Clinical correlates of infections
The association between infection rates in post-transplant year 1 and
demographic characteristics of recipients and donors, and transplant
characteristics, were examined using Poisson regression. Analysis
was limited to post-transplant year 1 only, due to nonconstant
hazards over the 3-year follow-up period, allowing inclusion of
patients undergoing transplants in 2002 and later. All analyses were
carried out using SAS version 9.1.3 (SAS Institute, Cary, NC, USA).
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Appendix A
ICD-9-CM codes used to identify specific infections
Infection Diagnosis codesa
Bacterial
Septicemiab 038.x
Tuberculosis 010.x-018.x
Other bacterialc 001.x-004.x, 008.0x-008.5x, 020.x-027.x, 030.x-036.x, 039.x-041.x, 073.x, 076.x, 080.x-083.x, 087.x-088.x, 091.x-100.x, 102.x-104.x, 137.x
Viral
Varicella-zoster 052.x-053.x
Herpes simplex 054.x
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Hepatitis B 070.2x, 070.3x
Hepatitis C 070.41, 070.44, 070.51, 070.54
Hepatitis (other) 070.0x-070.1x, 070.42, 070.43, 070.49, 070.52, 070.53, 070.59, 070.6x, 070.9x
Cytomegalovirus 078.5x
Other virald 008.6x, 008.8x, 045.x-051.x, 055.x-057.x, 060.x-066.x, 071.x, 072.x, 074.x, 075.x, 078.2x-078.4x, 078.6x, 078.7x, 079.51, 079.52, 079.81
Fungal 112.0x, 112.4x, 112.5x, 112.81, 112.83, 112.84, 112.85, 112.89, 112.9x, 114.x-117.x
Parasitic
Pneumocystosise136.3x
Other parasiticf 006.x, 007.x, 084.x-086.x, 120.x-131.x, 136.2x, 136.4x, 136.5x
Otherg 009.x, 101.x, 136.9x
ax, any valid fourth and/or fifth digit.
bSepticemia includes streptococcal, staphylococcal, pneumococcal, septicemia due to anaerobes, septicemia due to other Gram-negative organisms, or other specified or
unspecified organisms not classified elsewhere. This excludes septicemia due to anthrax, gonococcal, herpetic, meningococcal, septicemic plague, and bacteremia. According
to ICD-9-CM coding guidelines, bacteremia (and the associated code) is only the presence of bacteria in the blood, and not classifiable as causing systemic disease.
cOther bacterial includes cholera, typhoid and paratyphoid fevers, other salmonella infections, shigellosis, E. coli, Arizona group of paracolon bacilli, aerobacter aerogenes,
proteus, staphylococcus, pseudomonas, campylobacter, Yersinia enterocolitica, Clostridium difficile, other anaerobes, other Gram-negative bacteria, other bacterial intestinal
infection, bacterial enteritis unspecified, plague, tularemia, anthrax, brucellosis, glanders, melioidosis, rate-bite fever, other zoonotic bacterial diseases, leprosy, diseases due
to other mycobacteria, diphtheria, whooping cough, streptococcal sore throat and scarlet fever, erysipelas, meningococcal infection, actinomycotic infections, gas gangrene,
rhinoscleroma, Whipple’s disease, necrobacillosis, tropical pyomyositis, toxic shock syndrome, ornithosis, trachoma, typhus, rickettsioses, relapsing fever, other arthropod-
borne disease, syphilis, gonococcal infections, other venereal diseases, leptospirosis, yaws, pinta, other spirochetal infection, and late effects of tuberculosis.
dOther viral includes enteritis due to specified or unspecified virus, acute poliomyelitis, slow virus infection of central nervous system, meningitis due to enterovirus, other
enterovirus diseases of central nervous system, other nonarthropod-borne viral diseases of central nervous system, smallpox, cowpox and paravaccinia, measles, rubella, other
viral exanthemata, yellow fever, dengue, viral encephalitis, hemorrhagic fever, other arthropod-borne viral diseases, rabies, mumps, specified diseases due to coxsackie virus,
infectious mononucleosis, sweating fever, cat-scratch disease, foot-and-mouth disease, hemorrhagic nephrosonephritis, arenaviral hemorrhagic fever, HTLV-I, HTLV-II, and
hantavirus.
eThe causative agent P. carinii was reclassified as a fungus in 2001 and renamed P. jiroveci.62
fOther parasitic includes amebiasis, other protozoal intestinal diseases, malaria, leishmaniasis, trypanosomiasis, schistosomiasis, other trematode infections, echinococcosis,
other cestode infection, trichinosis, filarial infection and dracontiasis, ancylostomiasis and necatoriasis, helminthiases, unspecified intestinal parasitism, toxoplasmosis,
trichomoniasis, specified infections of free-living amoebae, psorospermiasis, and sarcosporidiosis.
gOther includes ill-defined intestinal infections, Vincent’s angina, and unspecified infectious and parasitic diseases.
Appendix Continued
Infection Diagnosis codesa
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